Metformin - A convenient alternative to insulin for Indian women with diabetes in pregnancy

Rai, Lavanya; Meenakshi, D Vijaya; Kamath, Asha

doi:10.4103/0019-5359.58878

Cited by 55 publications

(51 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…None of the women complained of severe gastrointestinal side-effects in the present study whereas 10.7% of metformin group in Rowan's study complained of severe gastroinestinal side effects. An Indian study which compared insulin and metformin for treatment of GDM and type 2 gestational diabetes mellitus during pregnancy reported better glycaemic control with metformin one week after starting therapy [8] .…”

Section: Discussionmentioning

confidence: 99%

Maternal and Fetal Outcome in Gestational Diabetes Mellitus (GDM) Treated with Diet and Metformin - A Preliminary Retrospective Analysis

Dasari¹

2011

TOPROCJ

View full text Add to dashboard Cite

Abstract:Context: Metformin therapy for treatment of GDM (Gestational Diabetes Mellitus) is not yet approved by FDA.Objectives: To assess the glycaemic control in women with GDM who received metformin therapy and to know the maternal side-effects and effects on the fetus-neonate. Material and Methods:A preliminary retrospective cohort analysis of 38 women with GDM who received metformin along with dietary advice for control of GDM. The maternal analysis included the time of initiation of metformin therapy, the glycaemic control, the need to add insulin and the side-effects. Fetal outcome analysis included Apgar score at birth, birth weight, neonatal hypoglycaemia, still birth rate and congenital malformations. The goals of glycaemic control were achieved by a pre-prandial Blood sugar of 60-70 mg%; post prandial blood sugar of 120-140mg%. Results:The mean age was 27.5 years and gestational age at diagnosis and initiation of metformin therapy was 24 weeks and 3 days. Twenty-four percent were diagnosed during first trimester. Ninety percent achieved glycaemic control with a dose of 1500 mg of metformin. Ten percent required an increment in dose up to 2250 mg and an addition of small dose of insulin only after 35 weeks of gestation. The mean birth weight was 3.12 kg and 13% were LGA. There were no cases of maternal or neonatal hypoglycaemia and no stillbirths, congenital anomalies or neonatal deaths. Conclusion:Metformin therapy resulted in optimum control of blood sugar in most of the women with GDM without any significant side-effects in the mother or in the fetus-neonate.

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal and Fetal Outcome in Gestational Diabetes Mellitus (GDM) Treated with Diet and Metformin - A Preliminary Retrospective Analysis

Dasari¹

2011

TOPROCJ

View full text Add to dashboard Cite

show abstract

“…3 Other studies also found similar results and suggested that metformin has a beneficial effect on the weight of mothers. 12,13 Our finding of mean birth weight of 3.14±0. …”

Section: Resultsmentioning

confidence: 77%

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Pranathi¹,

Devi

2018

ijmsci

View full text Add to dashboard Cite

“…Postprandial plasma glucose was lower in insulin group in this study. Two randomised trials have reported better glucose control among metformin users than that insulin users based on postprandial glucose levels (31,35) and on both fasting and postprandial values in an observational study of Rai et al (37) Some patients on metformin need additional insulin to meet glycaemic targets. In this study, 25% of GDM patients in the metformin group needed additional insulin compared to 14-46% in previous randomised trials comparing metformin with insulin in GDM patients.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Gestational Diabetes Mellitus: Insulin or Metformin?

Somani¹,

Sahana²,

Chaudhuri³

et al. 2016

jemds

View full text Add to dashboard Cite

BACKGROUNDMetformin has established as an ideal first-line treatment for type 2 diabetes and hypothetically a particularly attractive drug for use in pregnancy. Metformin is known to cross the placenta and its use in pregnancy has been limited by concerns regarding potential adverse effects on both the mother and the foetus. Randomised trials to assess the efficacy and safety of its use for Gestational Diabetes Mellitus (GDM) are lacking.

show abstract

Metformin - A convenient alternative to insulin for Indian women with diabetes in pregnancy

Cited by 55 publications

References 12 publications

Maternal and Fetal Outcome in Gestational Diabetes Mellitus (GDM) Treated with Diet and Metformin - A Preliminary Retrospective Analysis

Maternal and Fetal Outcome in Gestational Diabetes Mellitus (GDM) Treated with Diet and Metformin - A Preliminary Retrospective Analysis

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Treatment of Gestational Diabetes Mellitus: Insulin or Metformin?

Contact Info

Product

Resources

About